Medivation Files Definitive Consent Revocation Statement and Mails Letter to Stockholders
Blockbuster sales and takeover potential create an attractive risk/reward tradeoff for this speculative biotech.
We see opportunity as fleeing investors trigger an irrational sell-off.
Morningstar analysts see pharmaceuticals as 2010's hot zone for mergers and acquisitions.
Fancy names can't make up for bad businesses.